Search

Author/Creator Spigel, D R

1. 1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. (23rd October 2018)

Authors:
Gettinger, S; Beck, T; Yang, X; Telivala, B; Morgensztern, D; Velcheti, V; Ramalingam, S S; Schalper, K; Dajee, M; Ranck, A; Yang, R; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. (17th December 2018)

Authors:
Reck, M; Vicente, D; Ciuleanu, T; Gettinger, S; Peters, S; Horn, L; Audigier-Valette, C; Pardo, N; Juan-Vidal, O; Cheng, Y; Zhang, H; Shi, M; Wolf, J; Antonia, S J; Nakagawa, K; Selvaggi, G; Baudelet, C; Chang, H; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1144PResponses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. (23rd October 2018)

Authors:
Garon, E B; Wong, D J; Schneider, J G; Aljumaily, R; Korn, W M; Patel, M R; Autio, K A; Papadopoulos, K P; Naing, A; Gabrail, N; Munster, P N; Goldman, J; Hung, A; Oft, M; Leveque, J; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 414PDPhase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (23rd October 2018)

Authors:
Cho, B C; Perets, R; Bar, J; Ahn, M-J; Kim, D-W; Yoh, K; Nagrial, A; Spigel, D R; Lee, D H; Gutierrez, M; Kotasek, D; Siddiqi, S; Chain, A; Butts, B D; Zhang, Y; Li, X; Cyrus, J; Tse, A; Altura, R A; Rasco, D
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. (14th May 2018)

Authors:
Gerber, D E; Horn, L; Boyer, M; Sanborn, R; Natale, R; Palmero, R; Bidoli, P; Bondarenko, I; Germonpre, P; Ghizdavescu, D; Kotsakis, A; Lena, H; Losonczy, G; Park, K; Su, W -C; Tang, M; Lai, J; Kallinteris, N L; Shan, J S; Reck, M
Journal:
Annals of oncology
Issue:
Volume 29:Number 7(2018)
Page Start:
1548
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA64nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. (23rd October 2018)

Authors:
Spigel, D R; Jotte, R M; Ponce Aix, S; Gressot, L; Morgensztern, D; McCleod, M; Socinski, M A; Daniel, D; Juan-Vidal, O; Kim, E S; West, H J; Chen, T; Bhore, R; Ong, T J; Gridelli, C; Thomas, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 322PThree-year overall survival update from the PACIFIC trial. (24th November 2019)

Authors:
Wu, Y-L; Gray, J E; Villegas, A; Daniel, D B; Vicente, D; Murakami, S; Hui, R; Kurata, T; Chiappori, A; Lee, K H; Cho, B C; Planchard, D; Paz-Ares, L; Faivre-Finn, C; Vansteenkiste, J F; Spigel, D R; Taboada, M; Dennis, P A; Özgüroğlu, M; Antonia, S J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 531TiPCANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC. (24th November 2019)

Authors:
Cho, B C; Chang, G-C; Kim, Y-C; Geater, S; Saeteng, S; Yang, C-T; Goto, Y; Lu, S; Ardizzoni, A; Barlesi, F; De Marchi, P; Paz-Ares, L; Spigel, D R; Thomas, M; Garon, E B; Leung, M; Baum, J; Zewen, Z; Mookerjee, B; Yang, J C-H
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study. (15th December 2019)

Authors:
Herbst, R S; de Marinis, F; Giaccone, G; Reinmuth, N; Vergnenegre, A; Barrios, C H; Morise, M; Felip, E; Andric, Z; Geater, S; Ozguroglu, M; Mocci, S; McCleland, M; Zou, W; Enquist, I; Komatsubara, K; Deng, Y; Kuriki, H; Spigel, D R; Jassem, J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours. (15th December 2019)

Authors:
Reck, M; Cappuzzo, F; Rodriguez-Abreu, D; Cho, D C; Schwarz, J K; Riese, M J; Gupta, A; Chan, T; Saab, R; Singel, S; Lin, W; Tagliaferri, M; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗